Pharming Group N.V. announced its participation in investor conferences in April 2026, including the Needham Virtual Healthcare Conference and Van Lanschot Kempen Life Sciences Conference. The company also announced a positive CHMP (Committee for Medicinal Products for Human Use) opinion for Joenja® (leniolisib) for treating APDS in adult and pediatric patients 12 years and older, and filed its 2025 Annual Report on Form 20-F.

Pharming Group announced that Japan's Ministry of Health, Labour and Welfare has approved Joenja® (leniolisib) for treating APDS in patients aged 4 years and older. This marks the first approved treatment for APDS in Japan and the first global approval for children aged 4-11 with the disease. The approval was based on positive Phase III clinical trial data showing significant improvements in lymphadenopathy reduction and naïve B cell percentage.

Pomerantz Law Firm is investigating Pharming Group N.V. for potential securities fraud following the FDA's issuance of a Complete Response Letter rejecting the company's supplemental application for Joenja® (leniolisib) for pediatric patients. The FDA cited concerns about drug underexposure in lower weight patients and analytical method issues. The news triggered a 17.07% stock price decline on February 2, 2026.

Pharming Group received a Complete Response Letter from the FDA for its supplemental application to expand Joenja® (leniolisib) to children aged 4-11 with APDS. The FDA requested additional pediatric pharmacokinetic data to address concerns about potential underexposure in lower weight patients and clarification on analytical batch testing methods. Pharming plans to work with the FDA to address these issues and request a Type A meeting for resubmission. The existing approval for patients 12 years and older remains unaffected.

Pharming Group N.V. announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. Lynard brings over 20 years of global finance leadership experience in life sciences, previously serving as CFO at Schoeller Allibert, Zentiva, and holding senior roles at Gilead Sciences.

Pharming Group N.V., a global biopharmaceutical company, announces that its management team will participate in the 37th Annual Roth Conference in March 2025, where they will hold a fireside chat and be available for one-on-one meetings.

Pharming Group N.V., a global biopharmaceutical company, announces that its management team will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025.

Pharming Group N.V. announced a recommended public cash offer to acquire all outstanding shares of Abliva AB, a biotechnology company focused on developing treatments for mitochondrial diseases. Abliva's lead product, KL1333, is currently in a pivotal clinical trial and has shown positive results in a proof-of-concept study.

Pharming Group N.V., a global biopharmaceutical company, announces that its CEO will present at the Jefferies London Healthcare Conference 2024 on November 20, 2024.

Pharming Group (PHAR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session. Impinj, Inc. (NASDAQ: PI) shares rose 31% to $65.06 after the company reported better-than-expected third-quarter revenue results. Bel Fuse Inc. (NASDAQ: BELFB) surged 23.4% to $48.61 after the company reported third-quarter financial results. Endeavor Group Holdings, Inc. (NYSE: EDR) gained 22.2% to $21.65 after the company announced a review of strategic alternatives. ImmunityBio, Inc. (NASDAQ: IBRX) rose 21.7% to $1.92. The FDA accepted ImmunityBio's resubmission of its Biologics License Application for N-803 as complete. First Foundation Inc. (NYSE: FFWM) shares climbed 13.9% to $5.57 following upbeat quarterly results. Blueprint Medicines Corporation (NASDAQ: BPMC) climbed 19.4% to $52.49 following strong quarterly results. Sunnova Energy International Inc. (NYSE: NOVA) rose 17.3% to $9.40 following third-quarter results. NETGEAR, Inc. (NASDAQ: NTGR) gained 15.5% to $12.05 after the company reported better-than-expected third-quarter financial results. Pharming Group N.V. (NASDAQ: PHAR) rose 13.8% to $11.38 after the company reported a year-over-year increase in third-quarter revenue results. Eagle Bancorp, Inc. (NASDAQ: EGBN) climbed 13% to $19.97 after the company reported ...

iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.